Estropipate
Ogen (estropipate) is a small molecule pharmaceutical. Estropipate was first approved as Ogen 5 on 1982-01-01. It is used to treat hot flashes, hypogonadism, menopause, menorrhagia, and premature menopause amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Ogen (discontinued: Estropipate, Ogen, Ortho-est)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| estropipate | ANDA | 2012-03-14 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
255 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | 7 | 8 | 19 | 15 | 4 | 52 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | 1 | 3 | 8 | 13 |
| Infertility | D007246 | EFO_0000545 | — | 2 | — | — | 2 | 4 | 8 |
| Syndrome | D013577 | — | — | — | 2 | 1 | 1 | 3 | 7 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | 1 | 2 | 6 |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | 1 | 5 | 6 |
| Dysmenorrhea | D004412 | — | N94.6 | — | — | 4 | 1 | — | 5 |
| Menstruation disturbances | D008599 | — | N91.5 | — | 1 | 3 | 1 | — | 5 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | 1 | 3 | 4 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 1 | 1 | 2 | 4 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 34 | — | 3 | — | — | 37 |
| Premenstrual syndrome | D011293 | — | N94.3 | — | 2 | 3 | — | 1 | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | 1 | — | 4 | 6 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | — | 1 | — | 4 | 5 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | 2 | 1 | — | — | 2 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | 1 | — | 1 | 2 |
| Premature menopause | D008594 | — | E28.31 | — | — | 1 | — | 1 | 2 |
| Ovulation | D010060 | — | — | — | 1 | 1 | — | — | 2 |
| Premenstrual dysphoric disorder | D065446 | — | F32.81 | — | 1 | 1 | — | — | 2 |
| Anorexia | D000855 | — | R63.0 | — | 1 | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 4 | 2 | — | — | 1 | 7 |
| Metrorrhagia | D008796 | — | N92.1 | — | 3 | — | — | 2 | 5 |
| Ovulation inhibition | D034445 | — | — | — | 2 | — | — | — | 2 |
| Feeding and eating disorders | D001068 | — | F50 | — | 1 | — | — | — | 1 |
| Hemostasis | D006487 | — | — | — | 1 | — | — | — | 1 |
| Acromegaly | D000172 | — | — | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
| Habitual abortion | D000026 | EFO_1000954 | N96 | — | 1 | — | — | — | 1 |
| Bone density | D015519 | EFO_0003923 | M85 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 8 | — | — | — | — | 8 |
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | 2 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | — | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 3 | — | — | — | — | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 3 | — | — | — | — | 3 |
| Pharmacokinetics | D010599 | — | — | 3 | — | — | — | — | 3 |
| Overweight | D050177 | — | E66.3 | 2 | — | — | — | 1 | 3 |
| Female infertility | D007247 | EFO_0008560 | N97 | 2 | — | — | — | — | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 2 | — | — | — | — | 2 |
Show 15 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | — | — | 2 | 2 |
| Thromboembolism | D013923 | — | — | — | — | — | — | 2 | 2 |
| Venous thrombosis | D020246 | — | I82.40 | — | — | — | — | 2 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 2 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 2 | 2 |
| Coronary disease | D003327 | — | — | — | — | — | — | 2 | 2 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 2 | 2 |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | — | — | — | 1 | 1 |
| Amenorrhea | D000568 | — | N91.2 | — | — | — | — | 1 | 1 |
Show 24 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Estropipate |
| INN | — |
| Description | Estropipate is a steroid sulfate and a piperazinium salt. It is functionally related to an estrone. |
| Classification | Small molecule |
| Drug class | estrogens; atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O |
Identifiers
| PDB | — |
| CAS-ID | 7280-37-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200980 |
| ChEBI ID | — |
| PubChem CID | 5284555 |
| DrugBank | DB04574 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Estropipate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 139 documents
View more details
Safety
Black-box Warning
Black-box warning for: Estropipate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
731 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use